Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares

Hepion Pharmaceuticals, Inc.

Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.
Gross proceeds from the private placement were $700,000, and the offering closed on the same date.
The shares were issued in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Gary Stetz, Interim CEO, signed the 8-K filing on behalf of Hepion Pharmaceuticals.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.